ACCURIUS THERAPEUTICS, INC.

Address: 213 EAST ST LEXINGTON, MA 02420-1924
County: MIDDLESEX
Country: UNITED STATES
UEI: QDZQGEE1TAX3

Issue Date FY

Legal Entity Zip Code

Issue Date FY: 2026 ( Subtotal = $0 )

2026

2024

ACCURIUS THERAPEUTICS, INC.

213 EAST ST

LEXINGTON

02420-1924

MIDDLESEX

USA

R44CA287806

Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)

000

NIH

1/9/2026

2026

2024

ACCURIUS THERAPEUTICS, INC.

213 EAST ST

LEXINGTON

02420-1924

MIDDLESEX

USA

R44CA287806

Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)

001

NIH

2/9/2026

Issue Date FY: 2025 ( Subtotal = $0 )

2025

2023

ACCURIUS THERAPEUTICS, INC.

213 EAST ST

LEXINGTON

02420-1924

MIDDLESEX

USA

R44CA287806

Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)

000

NIH

3/18/2025

Issue Date FY: 2024 ( Subtotal = $1,000,000 )

2024

ACCURIUS THERAPEUTICS, INC.

213 EAST ST

LEXINGTON

02420-1924

MIDDLESEX

USA

R44CA287806

Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)

002

NIH

9/4/2024

$1,000,000

2024

2023

ACCURIUS THERAPEUTICS, INC.

213 EAST ST

LEXINGTON

02420-1924

MIDDLESEX

USA

R44CA287806

Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)

000

NIH

11/13/2023

2024

2023

ACCURIUS THERAPEUTICS, INC.

213 EAST ST

LEXINGTON

02420-1924

MIDDLESEX

USA

R44CA287806

Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)

001

NIH

9/4/2024

Issue Date FY: 2023 ( Subtotal = $399,999 )

2023

ACCURIUS THERAPEUTICS, INC.

213 EAST ST

LEXINGTON

02420-1924

MIDDLESEX

USA

R44CA287806

Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)

000

NIH

9/21/2023

$399,999

All Categories

About

Search

Reports

Data Submission

Recipient Information

ACCURIUS THERAPEUTICS, INC.

Address: 213 EAST ST LEXINGTON, MA 02420-1924

County: MIDDLESEX

Country: UNITED STATES

UEI: QDZQGEE1TAX3

Issue Date FY Summary

Issue Date FY by OPDIV

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer